<DOC>
	<DOCNO>NCT02700048</DOCNO>
	<brief_summary>This single center , single-blind randomize cross design trial compare impact intra-nasal naloxone vs. intra-nasal saline administration experimental hypoglycemia day one responses experimental hypoglycemia day two . Investigators intend enroll 18 individual obtain complete data set 15 participant . Expected duration subject participation 10-12 week . This study consist two 2-day intervention visit separate approximately 8 week .</brief_summary>
	<brief_title>Intra-nasal Naloxone Treatment Impaired Awareness Hypoglycemia</brief_title>
	<detailed_description>This single center , single-blinded randomize cross design trial , compare impact IN naloxone v . IN saline experimental hypoglycemia day one responses experimental hypoglycemia day two . 18 participant study twice , 8 week apart . On occasion participant undergo 2 hour hypoglycemic clamp ( target 50 mg/dl ) morning afternoon day one morning day 2 . During morning clamp , sample collect later measurement serum epinephrine , glucagon cortisol level participant ask complete hypoglycemia symptom questionnaire . 3 intranasal dos ( 4 mg ) naloxone hydrochloride IN saline administer subject day 1 . Plasma collect measurement naloxone concentration day 1 primary outcome difference peak epinephrine secretion morning episode hypoglycemia day one two , thus participant two observation : one naloxone experiment one saline experiment . Secondary endpoint naloxone pharmacokinetics include maximum concentration ( Cmax ) , time maximum concentration ( Tmax ) area curve ( AUC )</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Unconsciousness</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>1 . Subjects capable give informed consent . 2 . Female subject must postmenopausal least 1 year , surgically incapable bearing child , practice least one follow method contraception three month prior , study : hormonal , intrauterine device ( IUD ) , barrier method combination spermicide . 3 . Subject medication free , hormonal birth control , 48 hour 24 hour study drug administration . If need medication identify time period , discuss approve PI . 1 . Women pregnant . 2 . Women breastfeed . 3 . Subject know hypersensitivity naloxone . 4 . Subject hypertension 5 . Subject significant history cardiac , neurologic , psychiatric , oncologic , endocrine , metabolic , renal hepatic disease 6 . Subject take used investigational drug device 30 day prior screen . 7 . Subject take either prescribed counter medication 48 hour prior study drug administration either study day , hormonal birth control . 8 . History narcotic heroin abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>type 1 diabetes</keyword>
	<keyword>hypoglycemia</keyword>
	<keyword>hypoglycemia unawareness</keyword>
</DOC>